**Toll-like receptors 2 and 6 mediate apoptosis and inflammation in ischemic skeletal myotubes**

Hemanshu Patel¹, Cissy Yong¹, Ali Navi¹, Sidney G Shaw², Xu Shiwen³, David Abraham³, Daryll M Baker¹ and Janice CS Tsui¹

1. Division of Surgery & Interventional Science, University College London, Royal Free Campus, London, UK
2. Department of Clinical Experimental Research, University of Bern, Bern, Switzerland
3. Centre for Rheumatology & Connective Tissue Disease, University College London, Royal Free Campus, London, UK

**Introduction**

Peripheral artery disease (PAD) is a major cause of morbidity and mortality and is caused by the accumulation of atherosclerotic plaques within the lower limb arteries. Critical limb ischaemia (CLI) results from progression of this disease leading to chronic muscle ischaemia with tissue inflammation, necrosis and apoptosis. Patients with CLI present with rest pain with or without ulcers or gangrene. At this stage limb salvage requires surgical or endovascular attempts to improve blood flow, however in some patients revascularisation is not possible. An increasing number of studies show that even successful revascularisation does not always lead to improvements in symptoms, functional status or quality of life. Indeed 34% of patients with CLI undergo major limb amputation within 12 months. The lack of improvement in symptoms in patients despite revascularisation is due in part to a myopathy within the ischaemic muscle. The pathophysiology of skeletal muscle damage following ischaemia is unclear but a number of detrimental physiological and biochemical changes have been identified. However the mechanism of how hypoxia/ischaemia activates the damaging pathways in muscle are yet to be elucidated.

Toll-Like receptors (TLRs) are pathogen recognition receptors (PRR) of the innate immune system. They are type 1 membrane glycoproteins that contain an external ligand-binding leucine-rich repeat (LRR) motif and a cytoplasmic signalling domain that is similar to the Interleukin-1 (IL-1) receptor and thus termed the Toll/IL-1 receptor (TIR) domain. So far 11 TLRs (TLR 1-11) are thought to be functional in humans and despite their documented role in innate immunity they are widely expressed by both immune and non-immune cells including skeletal muscle. TLRs recognise and are activated by pathogen associated molecular patterns (PAMPs) which are microbial molecules that alert the host cell of the presence of invading organisms such as bacteria and viruses. In addition to PAMPs, TLRs are also stimulated by host derived molecules that are released during tissue injury. Endogenous ligands such as high mobility group box 1 protein (HMGB-1) and heat shock
proteins (HSPs) and hyaluronan (12) have been implicated in ischaemia-induced organ damage.

Ligand binding by PAMPs or endogenous molecules leads to TLR dimerization which contributes to ligand specificity. All TLRs form homodimers except TLR1, 2 and 6: TLR2 can heterodimerise with TLR1 or 6 (13) depending on the stimulating ligand. Exogenous or endogenous ligand stimulation of the TLR signalling pathways, of which there are two distinct types, leads to activation of transcription factors such as nuclear factor κB (NF-κB), activator protein 1 (AP-1) and the interferon regulatory factors. This in turn leads to upregulation of pro-inflammatory cytokines such as tumour necrosis factor α (TNF-α), interleukins 1 and 6 (IL-1 & 6) and type 1 interferons (IFN). Further, TLR activation has been reported to directly cause apoptosis via Fas-associated death domain protein (FADD) and caspase 8 (14).

Signal transduction following TLR stimulation is dependent upon the TIR domain binding to an adapter protein. There are four adapter proteins that are involved: myeloid differentiation primary response protein 88 (MyD88), TIR domain-containing adapter protein (TIRAP/Mal), TIR domain-containing adapter inducing IFNβ (TRIF) and TRIF-related adapter molecule (TRAM) (15). The two distinct TLR signalling pathways are the MyD88 dependent and the MyD88 independent pathways whose main adapter proteins are MyD88 and TRIF respectively. All TLRs signal via the MyD88 dependent pathway apart from TLR3 which signals via the MyD88 independent pathway, whilst TLR 4 can signal via either signalling mechanism. The subsequent propagation of the signalling pathway involves the interleukin-1 receptor associated kinase (IRAK) and MAP kinase family. In the TLR signalling pathway the quiescent NF-κB is sequestered by the inhibitor of NF-κB (IκB) protein. Following TLR stimulation and signal transduction, IκB protein is phosphorylated and polyubiquitylated which releases NF-κB to translocate to the nucleus and activate gene transcription.

There is emerging evidence suggesting that TLRs play an important role in ischaemia and ischaemia/reperfusion induced tissue damage in the kidneys, liver, central nervous and cardiovascular systems (16). In particular TLR2 and 4 activation has been strongly associated with ischaemia-induced organ damage (17, 18). TLR2 and 4 knockout mice have been shown to be protected against ischaemia-induced liver (19), renal (20) and myocardial (21) injury. Further studies have shown that this protective effect is associated with a reduction in pro-inflammatory cytokine expression (22) and NF-κB nuclear translocation (21). Despite this strong association between TLRs and ischaemia-induced pathogenesis, very little work has focused on the role that TLRs play in skeletal muscle damage in CLI.

Current treatments for CLI are aimed at improving blood flow. However there is significant evidence to suggest that this does not always help improve patient symptoms. We have
therefore taken a novel approach of studying the affected end organ, i.e. the skeletal muscle itself in order to understand whether TLR2 and TLR6 play a role in the ischaemia-induced muscle damage. A better understanding of this pathological process may identify potential therapeutic targets that may be used in conjunction with revascularisation.

Methods

Human gastrocnemius muscle biopsy

Open gastrocnemius muscle biopsies were obtained from patients undergoing perigenicular amputation for CLI and non-ischaemic control samples were obtained from patients undergoing great saphenous vein harvesting for coronary artery bypass grafting. Twelve patients from each group were biopsied. The biopsy is taken as an excisional biopsy rather than using a biopsy needle. Thus the sample size of the biopsy is approximately 4mm by 4mm. At least 3 biopsies were taken from the patient with PAD whilst 1 sample per patient was taken from the control patients. The sample is taken from the medial head of the gastrocnemius muscle and any areas with macroscopic necrosis were avoided. To ensure that none of the control patients had flow limiting PAD, all patients with an ankle-brachial pressure index (ABPI) of <0.9 were excluded from the control group. In addition any patient with an infected ulcer or trauma were also excluded from the sample collection. There was no significant difference in the age related risk factors between the 2 groups (Figure 1a). We have previously shown that hypoxia-inducible factor 1α a marker of hypoxia is elevated in muscle samples from patients with CLI compared to control (23). The same technique was used to harvest the muscle samples in both groups and the tissue was snap frozen in liquid nitrogen and stored at -80°C until use.

Cell cultures

The C2C12 mouse myoblast cell line (European Collection of Cell Cultures (ECACC) no. 91031101, passage no. 13, Salisbury, UK) was plated onto 12-well culture plates (BD Falcon™, cat. no. 351143, Flintshire, UK) or 8-well chamber slides (BD Falcon, cat. No. 354108, Flintshire, UK) and cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Paisley, Scotland) supplemented with 10% fetal calf serum, penicillin (100U/mL), streptomycin (100 µg/mL) and amphotericin B (25 µg/mL, all from Gibco). At 80% confluence, cells were switched to differentiation medium containing DMEM with 2% horse serum penicillin (100U/mL), streptomycin (100 µg/mL) and amphotericin B (25 µg/mL, all from Gibco). Differentiation was confirmed by changes in morphology (supplementary...
Figure 1) as well changes in the expression of myogenin protein. Myogenin is preferentially expressed in skeletal myotubes but not myoblasts (23). Following differentiation, usually at day 7-8, myotubes were exposed to simulated ischaemia or normoxia with or without relevant pre-treatments.

**Simulated ischaemia**

We have developed a model of simulated ischaemia that has previously been described (23). Chronic ischaemia is difficult to replicate in vitro, however the aim of the simulated ischaemia model was to create an in vitro environment that matched the parameters of chronic ischaemia such as PO$_2$, CO$_2$, pH, apoptosis and lactate dehydrogenase release which have been demonstrated in skeletal muscle of patients with CLI. Briefly, 24 hours following culture media change, myotubes (in open dishes) were exposed to 20% CO$_2$+80% N$_2$ (British Oxygen, Luton, UK) in hypoxic chambers (Modular Incubator Chamber, MIC-101; Billups-Rothenberg, Del Mar, CA, USA). The chamber was flushed with gas at 10 l/min for 20 min and then sealed. The apparatus was placed in an incubator at 37°C for 8, 24 and 72h. Control myotubes were maintained under normoxic conditions (21% O$_2$+5% CO$_2$) for 8h. The oxygen tension of the ischaemic media was 6.8kPa compared to 16.2 kPa in control media. The media was collected and centrifuged at 1600 g for 5 min at 4°C and stored at −20°C. The myotube monolayer was harvested on ice, washed with cold PBS and following this, 75 μl RIPA buffer 1 × solution (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris, pH 8.0; product number R0278; Sigma Aldrich, St Louis, MO, USA) and 75 μl of Laemmli buffer was added to each well. The monolayer was scrapped with a cell scrapper and collected into a 1.5 mL Eppendorf tube using a syringe with a 23 G needle. A total of 5 μl (2–5%) of 2-mercaptoethanol was added to the cell extract, which was then heated at 95°C for 5 min. Extracts were then centrifuged at 1600 g for 5 min at 4°C. The supernatant was collected and stored at −80°C for western blot analysis.

**Pre-treatment studies**

To investigate the role of TLR2 and TLR6 and the downstream signalling pathways involved in ischaemia-induced apoptosis and IL-6 induction, the following agonist and neutralising antibodies/inhibitors were used: TLR2/6 agonist PAM2CSK4 (10μg/mL; EMC-MicroCollections, Tuebingen, Germany) was incubated with myotubes for 8h; anti-TLR2 antibody (50μg/mL; T2.5; eBioscience, San Diego, USA) and anti-TLR6 antibody (1.25μg/mL; pab-hstlr6; Invivogen, San Diego, USA) was added to the myotubes 30mins prior to incubating in ischaemia or added with PAM2CSK4; MyD88 inhibitor (100μg/mL; tlr1-pimyd; Invivogen) was added 24h prior to incubating in ischaemia; TRIF inhibitor (20μM; tlr1-pitrif;
Invivogen) was added 6h prior to incubating in ischaemia; and NF-κB inhibitor (10μM; Celastrol ant-cls; Invivogen) was added just before incubating in ischaemia (all based on dose-ranging experiments; data not shown).

Immunocytochemistry

TLR2 and TLR6 co-localisation

OCT embedded gastrocnemius muscle was cut into 6μm sections and mounted for double-immunofluorescence staining. Sections were fixed with ice cold acetone and blocked with 10% chicken serum. Following this, sections were incubated in rabbit anti-human TLR2 antibody (1:50, sc-10739; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and goat anti-human TLR6 antibody (1:50, sc-5657; Santa Cruz Biotechnology). After incubation with primary antibody or its IgG isotype control for 1h at room temperature, slides were washed with PBS and treated with Texas Red-chicken Anti-Rabbit (1:200, Invitrogen) and FITC-chicken Anti-goat (1:200, Invitrogen) secondary antibodies. The slides were washed with PBS and coverslips were mounted using VECTASHIELD® mounting medium containing DAPI. The images were viewed using a fluorescence microscope (Axioscop 2; Carl Zeiss Micro-imaging).

Apoptosis

Cleaved caspase-3 expression was used to assess apoptosis. Chamber slides were removed from the hypoxic chamber and the myotube monolayer was fixed in 4% formaldehyde for 5 min. Serum block was performed with 10% goat serum and cells were incubated with Cleaved caspase-3 (Asp175) antibody (1:50 Cell Signalling Technology, Danvers, MA, USA) or its IgG isotype control for 1h at room temperature. Slides were then treated with Texas Red-X goat anti-mouse IgG antibody (Invitrogen), in 1:1000 dilution for 60 min in the dark at room temperature. The slides were washed with PBS and coverslips were mounted using VECTASHIELD® mounting medium containing DAPI. The images were viewed using a fluorescence microscope.

Western blot analyses

Equal amounts of denatured protein were loaded per lane (24μg) and were separated on 12% Tris-glycine gel followed by transfer onto a nitrocellulose membrane (Hybond-C extra; GE Healthcare Life Sciences, Buckinghamshire, UK). The membranes were blocked with 5% milk in PBS/0.1% Tween 20 and incubated overnight at 4°C with the following antibodies:
TLR2 (1:500; sc-10739; Santa Cruz), TLR6 (1:500; sc5661; Santa Cruz), TLR6 (1:500; ab-71429; Abcam, Cambridge, UK), NF-κB (1:1000; C22B4; Cell Signalling), Phospho-NF-κB (1:2000; 93H1; Cell Signalling); IkBα (1:1000; Cell Signalling); Phospho-IkBα (1:1000; Cell Signalling); cleaved caspase-3 (1:1000; 9661; Cell Signalling); BAX (1:500; sc-526; Santa Cruz), BCL-2 (1:500; sc-783; Santa Cruz), HMGB-1 (1:1000; ab18256; Abcam) and β-tubulin-loading control (1:10000; ab4074; Abcam). The membranes were then washed and incubated with horseradish peroxidase-linked corresponding secondary antibody at room temperature. The membrane was developed using chemiluminescent substrate (Amersham ECL Plus™ Western Blotting Detection Reagent; GE Healthcare Life Sciences) and the blots were developed against photographic film (Amersham Hyperfilm ECL, GE Healthcare Life Sciences). Band intensities were determined by densitometry using Biospectrum® AC imaging system (UVP, Upland, CA, USA).

**Immunoprecipitation**

Ischaemic and control C2C12 myotube monolayers were lysed with lysis buffer (1% SDS, 1.0mM sodium-orthovandate, 10MM Tris pH 7.4). The lysate was than boiled for 5mins, sonicated and centrifuged. 100μl of lysate was incubated at 4°C for 1h with 2μg anti-TLR2 (sc10739) or anti-TLR6 (sc5661), 400μl H2O and 2X immunoprecipitation buffer (2% Triton X-100, 300mM NaCL, 20mM Tris pH 7.4, 2mN EDTA, 2mM EGTA pH 8.0, 0.4mM sodiumorthovandate, 0.4mM PMSF, 1% NP-40). Subsequently the lysate was incubated with 50μl protein G-Sepherose (P3296; Sigma-Aldrich, UK) for 30mins at 4°C with agitation. Bound proteins were than washed twice with 1X immunoprecipitation buffer and the pellet resuspended in 45μl 2X laemlli buffer. Immune complexes were separated by Tris-glycine, transferred to nitrocellulose, and immunoblotted with TLR2 or TLR6 antibodies. Following optimisation of the antibody and technique for the immunoprecipitation studies we did not include IgG control for further experiments. Proteins were visualized by using chemiluminescence followed by exposure to photographic film.

**IL-6 Assay**

IL-6 protein concentrations in the culture media were determined using an ELISA kit (Mouse IL-6 ELISA Ready-SET-Go!®, eBioscience, San Diego, USA) following the manufacturer’s protocol. Samples and known standards were assayed in triplicate. The lower detection limit was 4pg/mL.
Statistical Analysis

Data was analysed with GraphPad Prism software, version 5. Parametric data were compared using a 2-tailed Student’s T-test and Analysis Of Variance (ANOVA)/Turkey HSD test, values represent mean±SE. Non-parametric data were described using median± range and were compared using a 2-tailed Mann-Whitney U test. P-value <0.05 was considered statistically significant.

Informed Consent Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Written informed consent was obtained from patients with prior approval from the Royal Free & Medical School Research Ethics Committee (REC Ref: 29-2000).

No animal studies were carried out by the authors for this article.

Results

**TLR2 and TLR6 protein expression is upregulated in critically ischaemic muscle and in C2C12 myotubes exposed to simulated ischaemia**

TLR1-7 have been shown to be expressed in skeletal muscle (9) and a number of studies have demonstrated that their expression is upregulated following ischaemia in various organ systems. However previous studies have not looked at the effect skeletal muscle ischaemia on TLR expression. We found a significant upregulation of TLR2 (P=0.004) and 6 (p=0.002) protein expression in muscle from patients with CLI (Figure 1b & d). During our optimisation of the in vitro ischaemia model we investigated different durations of hypoxia, thus exposing the myotubes to 8h, 24h and 72h. We found that 8h was the optimum duration for the myotubes to be exposed to ischaemia in terms of ischaemic parameters such as the pH, PO2, CO2 and lactate. Longer periods of exposure to hypoxia began to effect the viability of the myotubes. We observed that 8h and 24h ischaemia did not have a significant effect on TLR2 and TLR6 expression (Data not shown). However myotubes exposed to 72h ischaemia showed a significant upregulation of TLR2 (P= 0.006) and 6 (P=0.0014) protein expression (Data not shown).

**TLR2 and 6 co-localise and co-immunoprecipitate in muscle following ischaemia with subsequent activation of the TLR signalling pathway**
TLR 2 heterodimerises with TLR1 or 6 depending on the ligand that is presented. We found increased TLR2 and TLR6 co-localisation in ischaemic human muscle (Data not shown) as well as co-immunoprecipitation of TLR2 and TLR6 following ischaemia (Figure 1f). This would suggest that ischaemia leads to TLR2 and TLR6 heterodimerisation and activation of the signalling pathway. In its inactive form NF-κB is bound to the inhibitory complex IκBα. Following TLR pathway activation, IκBα is phosphorylated and NF-κB is released. Further, optimal NF-κB activation occurs following phosphorylation of the p65 sub-unit of NF-κB. Considering these principles we assessed protein expression of IκB and NF-κB (p65) as well as their phosphorylated forms in control and ischaemic C2C12 myotubes. Protein expression of both IκB (P=0.0028; Figure 2a) and NF-κB (P=0.003; Figure 2c) was reduced in ischaemic myotubes. Conversely there was significantly increased expression of the phosphorylated form of IκBα (P<0.0001; Figure 2a) and NF-κB (P=0.01; Figure 2c) in ischaemic but not control myotubes. This indicated that simulated ischaemia not only leads to TLR2 and TLR6 heterodimerisation but also activation of the TLR signalling pathway and subsequent NF-κB activation by its phosphorylation.

**TLR2 and 6 blockade reduces ischaemia-induced apoptosis**

Increased apoptosis has been demonstrated in skeletal muscle of patients with PAD (1). We therefore evaluated the effect of ischaemia on myotube apoptosis. We found that ischaemia increased apoptosis as shown by increased BCL2-associated X protein (BAX) (P=0.005; Figure 3b) and decreased B-cell lymphoma 2 (BCL2) (P=0.002; Figure 3b.) expression. This finding was confirmed by increased cleaved caspase-3 expression on western blot (Figure 3d) and immunofluorescence (Figure 3a). Further, neutralising anti-TLR2 (P<0.01; Figure 3d) and anti-TLR6 (P<0.01; Figure 3d) antibodies reduced ischaemia-induced apoptosis as represented by reduced cleaved caspase-3 protein expression on western blot. These findings suggest that ischaemia-induced apoptosis is mediated via TLR2 and TLR6 activation in skeletal muscle.

**Ischaemia-induces skeletal muscle inflammation via TLR2 and TLR6**

Patients with PAD have been reported to have high levels of circulating cytokines such as TNF-α and IL-6 (24) and ischaemia itself is known to trigger the release of inflammatory cytokines in a variety of organs. We found that IL-6 release was significantly upregulated in the media of the ischaemic myotubes (P<0.01; Figure 4a). In addition, the TLR2 and TLR6 agonist PAM2CSK4 also increased IL-6 (P<0.01; Figure 4a) release in the absence of an ischaemic stimuli. Further, neutralising anti-TLR2 (P<0.01) and 6 (P<0.01) antibodies both reduced the ischaemia-induced IL-6 release indicating that the IL-6 release was mediated via the activation of these 2 receptors (Figure 4a).
Ischaemia-induced IL-6 generation and apoptosis is mediated via MyD88 signalling pathway and NF-κB activation

TLR signal transduction is mediated via the MyD88 dependent and MyD88 independent pathways and this leads to the activation of a number of transcription factors such as NF-κB and AP-1. We sought to determine whether both pathways are utilised in ischaemia-induced apoptosis and IL-6 release and whether IL-6 generation is a result of NF-κB activation. C2C12 myotubes were pre-treated with a MyD88, TRIF or NF-κB inhibitor prior to exposure to 8h simulated ischaemia. The C2C12 myotubes pre-treated with the MyD88 (P<0.01) and NF-κB (P<0.01) inhibitors showed reduced IL-6 generation, whilst TRIF inhibition as well the MyD88 and TRIF control peptides did not reduce ischaemia-induced IL-6 release (Figure 4b). Further MyD88 inhibition but not TRIF inhibition reduced ischaemia-induced apoptosis as shown by the reduced cleaved caspase-3 expression (Figure 5a). My88 inhibition disrupted ischaemia-induced NF-κB phosphorylation and hence activation however TRIF inhibition did not abrogate ischaemia-induced NF-κB activation (Figure 5c).

Potential Endogenous Ligands

Among the endogenous ligands or damaged associated molecular patterns (DAMPs) that activate TLRs, HMGB-1 and the HSPs have been implicated in activating TLRs following an ischaemic insult. We therefore determined the expression of HMGB-1 and HSPs 60(25) and 70(26) in ischaemic C2C12 myotubes. We have found that following an ischaemic insult there was an increase in the expression of HMGB-1 (P=0.007; Figure 6a), HSPs 60 (P=0.0003; Figure 6c) and 70 (P<0.0001; Figure 6c)

Discussion

The management of CLI is pre-dominantly aimed at improving blood flow or in severe cases major amputation is required to prevent progression of gangrene. However despite successful improvement in blood flow to the ischaemic leg many patients still complain of no improvement of symptoms in terms of pain, exercise tolerance and quality of life and therefore deem the surgery to be unsuccessful. The exact pathophysiology as to why these patients have ongoing muscle dysfunction despite the restoration of blood flow is unclear. However emerging evidence suggests that this may be due to ischaemia-induced skeletal muscle damage and it is thought that inflammation plays a central role in this process (27). In support of the theory that inflammation plays an important role in skeletal muscle damage in CLI, it has been shown that raised levels of circulating pro-inflammatory cytokines such as TNFα, IL-6 and chemokines are found in patients with PAD (24).

The discovery of TLRs and their role in immunity and inflammation has led to significant advances in terms of understanding the pathophysiology of ischaemia and ischaemia/reperfusion mediated organ injury. In particular TLR2 and TLR4 have been
strongly implicated in myocardial injury following sustained ischaemia and TLR 2 (28) and TLR4 (29) knockout mice have been shown to have reduced myocardial infarct size. These emerging studies along with the fact TLRs are also expressed on skeletal muscle provide a potential understanding of how ischaemia in CLI patients causes skeletal muscle damage.

Preliminary studies using focussed RT-PCR microarray studies carried out in our lab demonstrated upregulation of gene expression of cell surface TLRs 1, 2, 4 and 6 as well as TLR-related cofactors MyD88 and CD14, and downstream targets IL6, IL8, IRAK1 in muscle from CLI patients. TLR2 upregulation was particularly marked; further, TLR 2 and 6 heterodimerisation had been described (30). Therefore we decided to investigate these 2 TLRs further. In the present study, we have not only shown that TLR2 and TLR6 are expressed on human skeletal muscle but that their expression is increased in ischaemic skeletal muscle. We observed from immunofluorescence staining that TLRs are expressed on endothelium (CD31), neutrophil (CD43), and macrophages (CD68) within muscle tissue. Given this wide spread expression as well as known expression of TLRs on muscle cells, we decided to focus here on the effect of ischaemia on muscle tissue TLR expression, where the TLR activation on individual cell types are likely to exert an autocrine/paracrine effect on the tissue as a whole. In order to understand the significance of this finding we have utilised an in vitro model of simulated ischaemia previously developed by our group. Significantly TLR2 and TLR6 expression was upregulated in the ischaemic C2C12 myotubes. These findings corroborate with other studies which have shown that ischaemia upregulates TLRs in various tissues both in vivo and in vitro. Our experiments have demonstrated that TLR2 and TLR6 also heterodimerise under ischaemic conditions suggesting ligand binding and activation of the downstream signalling pathway. Indeed we found that IκBα was phosphorylated following an ischaemic insult indicating activation of NFκB which is central to the translocation of NFκB into the nucleus and the subsequent induction of pro-inflammatory cytokines.

Several studies have shown that following ischaemia cellular death results due to apoptosis and increased apoptosis of skeletal muscle has also been demonstrated in patients with PAD. Our data supports that an ischaemic insult upregulates cellular apoptosis in muscle. We have also shown that ischaemia-induced apoptosis in skeletal muscle is reduced by neutralising anti-TLR2 and TLR6 antibodies indicating that ischaemia-induced apoptosis is mediated via TLR2 and TLR6. The mechanism for this is still poorly understood but studies have shown that TLR2 may promote apoptotic cell death via several pathways such as activation of the JNK-AP-1 (31) pathway or via a pathway involving Fas-associated death domain protein (FADD) and caspase 8 (14).

IL-6 is a potent inflammatory cytokine that plays a significant role in the pathogenesis of cell damage following ischaemia in various tissues. We have established that ischaemia results in an increase in IL-6 release by myotubes whilst inhibiting TLR2 and TLR6 reduced IL-6 production. This would suggest that TLR2 and TLR6 are important in the ischaemia-induced
upregulation of IL-6 and any subsequent muscle damage propagated by this inflammatory cytokine.

We further sought to elucidate which TLR signalling pathway is implicated in these potentially pathological processes. We found that ischaemia-induced NFκB phosphorylation, apoptosis and IL-6 production in skeletal muscle is mediated via the MyD88 dependent and not the MyD88 independent (TRIF Dependant pathway). The MyD88 pathway may therefore be a potential therapeutic target in reducing ischaemic muscle damage. In addition by targeting a specific pathway, potential side effects of any medical therapy would be kept to a minimum.

Several TLR2 and TLR6 endogenous ligands have been identified that are released in response to stress. In particular HMGB-1, HSPs 60 and 70 have already been implicated in the pathogenesis of renal, liver and myocardial damage following ischaemia. We have shown in our previous studies that there is upregulation in the expression of HMGB-1, HSPs 60 and 70 following ischaemia; further HMGB-1 and HSP 60 have been shown to co-localise with TLR2 and TLR4 (32, 33). Therefore, one can speculate that these endogenous ligands may be activating TLR2 and TLR6 and propagating the skeletal muscle damage in patients with limb ischaemia. However, we have yet to identify whether these potential endogenous ligands specifically activate TLR 2 and TLR 6 following skeletal muscle ischaemia or whether there is an alternative mechanism for their activation. Recombinant HMGB-1 has been shown to worsen myocardial injury following I/R whereas treatment with the HMGB-1 antagonist HMGB-1 box A reduced infarct size (11). Thus, it would be interesting to see whether antagonising HMGB-1, HSPs 60 or 70 may reduce skeletal muscle damage following an ischaemic insult.

This study has several limitations: analyses of our muscle biopsies from patients provided only observational evidence for the involvement of TLR2 and TLR6 in ischaemic skeletal muscle. Further investigation was carried out in an in vitro model where C2C12 myotubes were used. This is an established murine cell line which may not fully reflect the situation in human cells. In vitro models are also not representative of the complex in vivo conditions that occur. However, using a combination of patient tissue analyses and in vitro experiments has allowed us to start elucidating potential pathways for more detailed investigation. As previously mentioned other TLRs have shown to play a role in ischaemia induced damage (34). In particular TLR 2 has also been shown to heterodimerise with TLR1 under certain conditions. It would not be surprising that the other TLRs may be also be playing a role in skeletal muscle injury as the functional 11 TLRs mediate their signalling via the same pathways. Therefore it should be pointed out that whilst we have shown that TLR2 and TLR6 play role in ischaemia induced skeletal muscle damage future studies focusing on the other TLRs in particular TLR4 would be beneficial.

In conclusion we have shown that TLR2 and TLR6 are upregulated in skeletal muscle following ischaemia. The receptors heterodimerise leading to activation of the MyD88
signalling pathway with subsequent activation of NFκB. This results in upregulation of the inflammatory cytokine IL-6 as well as increase in muscle apoptosis. It is most likely that this results in an environment whereby the inflammatory milieu leads to a myopathy and thus limits the therapeutic effect of revascularisation. Our study has therefore identified potential therapeutic targets such as the MyD88 signalling pathway which may be blocked in order to prevent or reduce muscle damage. It is possible that medical therapy with the aim of reducing the skeletal muscle damage in conjunction with improvement in blood flow may provide symptomatic relief and improve functional outcomes.

Acknowledgements

We thank the theatre staff of The Heart Hospital and the Royal Free Hospital for helping with tissue collection.

Disclosures

None.

Funding

This work was supported by Circulation Foundation research fellowship (fellowship to H. Patel). J. Tsui and S. Shaw were supported by a Royal Society International Joint Project grant.

References


Figure Legends

Figure 1
(a) Table demonstrating patient characteristics including risk factors for atherosclerotic vascular disease. (b & d) Representative TLR2 and 6 western blots of control and CLI patient muscle samples. Blot was reprobed for β-Tubulin expression as control for protein loading. (c & e) Densitometric quantification of TLR 2 and 6 levels in CLI muscle, values are median and range, *p<0.01 compared to control, Mann-Whitney U Test, n=12. (f) TLR2 heterodimerises with TLR6 following ischaemia.

Figure 2
(a) Representative western blot showing downregulation of IκBα and upregulation of P- IκBα in C2C12 myotubes exposed to 8h of simulated ischaemia compared to control myotubes. Protein loading was consistent as shown by β-Tubulin levels. (b) Densitometric analyses of western blots, values are means ± standard error (SE), n = 3, *p<0.05 unpaired t-Test (c) Representative western blot showing downregulation of NF-κB and upregulation of P-NF-κB in C2C12 myotubes exposed to 8h of simulated ischaemia compared to control myotubes. Protein loading was consistent as shown by β-Tubulin levels. (d) Densitometric analyses of western blots, values are means ± SE, n = 3, *p<0.05 unpaired t-Test.

Figure 3
(a) Immunofluorescence staining for DAPI (blue) and cleaved caspase-3(green) was performed on control and ischaemic myotubes as well ischaemic myotubes incubated with neutralising anti-TLR2 antibody. There is increased cleaved caspase-3 staining in the ischaemic myotubes and significantly reduced cleaved caspase-3 staining in the ischaemic myotubes with anti-TLR2 antibody. (b) Representative western blot showing downregulation of BCL2 and upregulation of BAX in C2C12 myotubes exposed to 72h of simulated ischaemia compared to control myotubes. Protein loading was consistent as shown by β-Tubulin levels. (c) Densitometric analyses of western blot, values are means ± SE, n = 9. *p<0.05 unpaired t-Test. (d) Representative western blot showing increased cleaved caspase-3 expression following 8h simulated ischaemia. Protein loading was consistent as shown by β-Tubulin levels. (e) Densitometric analyses of western blots, values are means ± SE, n = 3. P<0.0001, ANOVA, *, denotes ischaemic myotubes; **, denotes Anti-TLR2 or 6 Antibody + ischaemic myotubes. Turkey HSD test, P <0.01 between: * and control myotubes; * and ** myotubes.
Figure 4
(a) IL-6 generation in C2C12 myotube supernatant was measured by ELISA. Myotubes were exposed to simulated ischaemia for 8h with or without anti-TLR2 or 6 antibodies. Values are mean ± SE, n = 9. P<0.0001, ANOVA. Turkey HSD test: * P <0.01 vs control, **P<0.01 vs control, †P<0.01 vs ischaemia, ††P<0.01 vs ischaemia. (b) IL-6 generation in C2C12 myotube supernatant was measured by ELISA. Myotubes were pre-treated with specific inhibitors or control peptides and exposed to simulated ischaemia for 8h. Values are mean ± SE, n= 9. P<0.0001, ANOVA. Turkey HSD test: * P <0.01 vs control, **P<0.01 vs ischaemia, †P<0.01 vs ischaemia.

Figure 5
(a) Representative western blot showing decreased Cleaved Caspase-3 expression. MyD88 inhibition significantly reduced ischaemia-induced Cleaved caspase-3 expression. Protein loading was consistent as shown by β-Tubulin levels. (b) Densitometric analyses of western blots, values are means ± SE, n = 9. P<0.0001, ANOVA. Turkey HSD test:* P <0.01 vs control, ** P<0.05 vs Ischaemia. (c) Representative western blot showing NF-κB and P-NF-κB expression in C2C12 myotubes exposed to 8h of simulated ischaemia. Protein loading was consistent as shown by β-Tubulin levels. (d) Densitometric analyses of western blots, values are means ± SE, n = 6. P<0.0001, ANOVA. Turkey HSD test: NF-κB expression; * P <0.01 vs control, ** P<0.01 vs Ischaemia, P-NF-κB expression; * P <0.05 vs control, ** P<0.01 vs Ischaemia.

Figure 6
(a) Representative western blot showing upregulation of HMGB-1 in C2C12 myotubes exposed to 8h of simulated ischaemia compared to control myotubes. Protein loading was consistent as shown by β-Tubulin levels. (b) Densitometric analyses of western blots, values are means ± SE, n = 6. *p<0.05 unpaired t-Test. (c) Representative western blot showing upregulation of HSPs 60 and 70 in C2C12 myotubes exposed to 8h of simulated ischaemia compared to control myotubes. Protein loading was consistent as shown by β-Tubulin levels. (d) Densitometric analyses of western blots, values are means ± SE, n = 6. *p<0.05 unpaired t-Test.

Supplementary Figure
Hematoxylin and eosin (H&E) staining confirming differentiation of C2C12 myoblasts (a) into multinucleated myotubes (b).
Figures

Figure 1

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control (n=4)</th>
<th>CLU (n=10)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age</td>
<td>67.17 ± 6.2</td>
<td>79.02 ± 1.7</td>
<td>NS</td>
</tr>
<tr>
<td>Mean AEB1</td>
<td>0.045 ± 0.07</td>
<td>0.036 ± 0.13</td>
<td>P=0.058</td>
</tr>
<tr>
<td>Male/Female</td>
<td>9/3</td>
<td>8/4</td>
<td>NS</td>
</tr>
<tr>
<td>Diabetes/Mellitus</td>
<td>4</td>
<td>5</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension</td>
<td>8</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td>Cigarette Smoking</td>
<td>9</td>
<td>10</td>
<td>NS</td>
</tr>
<tr>
<td>Hypoxia/Anoxia</td>
<td>9</td>
<td>9</td>
<td>NS</td>
</tr>
<tr>
<td>Statin therapy</td>
<td>10</td>
<td>8</td>
<td>NS</td>
</tr>
<tr>
<td>Aspirin therapy</td>
<td>10</td>
<td>11</td>
<td>NS</td>
</tr>
</tbody>
</table>

Figure 2

a) Control vs. Ischaemia

b) NF-κB

c) NF-κB

D) NF-κB

*Indicates significant difference.
Figure 1

Figure 2